Effectiveness of the association micronized N-Palmitoylethanolamine (PEA)-transpolydatin in the treatment of chronic pelvic pain related to endometriosis after laparoscopic assessment: a pilot study
Randomised controlled trialHumansWith transpolydatin
This study tested palmitoylethanolamide together with transpolydatin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Randomised controlled trial
- Subjects
- 61 subjects with endometriosis-related pelvic pain after first-line conservative laparoscopic surgery: 21 PEA-transpolydatin, 20 placebo, 20 celecoxib
- Dose used in the study
- Micronised PEA 400 mg plus transpolydatin 40 mg twice daily for 3 months; placebo for 3 months; or celecoxib 200 mg twice daily for 7 days
- Duration
- 3 months
- What was measured
- Pelvic pain, dysmenorrhoea and dyspareunia on a 10-point VAS and questionnaire before and after treatment
What the authors reported
The trial found:
- Dysmenorrhoea, dyspareunia and pelvic pain decreased markedly in all three groups.
- PEA-transpolydatin was more effective than placebo (P < 0.001).
- Celecoxib reduced pelvic pain more than PEA-transpolydatin or placebo.
Limits of this study
Pilot with about 20 per group. All women had recently had surgery, so much of the improvement is surgical. The celecoxib arm ran 7 days against 3 months for the others. The abstract calls the trial double-blind and does not say how the 7-day celecoxib arm was blinded.
Source
PubMed 21601979 · doi:10.1016/j.ejogrb.2011.04.011
Entry checked against the abstract, supplied by Devlin on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.